Exploiting radiation immunostimulatory effects to improve glioblastoma outcome - Université d'Angers Accéder directement au contenu
Article Dans Une Revue Neuro-Oncology Année : 2023

Exploiting radiation immunostimulatory effects to improve glioblastoma outcome

Résumé

Cancer treatment protocols depend on tumor type, localization, grade, and patient. Despite aggressive treatments, median survival of patients with Glioblastoma (GBM), the most common primary brain tumor in adults, does not exceed 18 months, and all patients eventually relapse. Thus, novel therapeutic approaches are urgently needed. Radiotherapy (RT) induces a multitude of alterations within the tumor ecosystem, ultimately modifying the degree of tumor immunogenicity at GBM relapse. The present manuscript reviews the diverse effects of RT radiotherapy on tumors, with a special focus on its immunomodulatory impact to finally discuss how RT could be exploited in GBM treatment through immunotherapy targeting. Indeed, while further experimental and clinical studies are definitively required to successfully translate preclinical results in clinical trials, current studies highlight the therapeutic potential of immunotherapy to uncover novel avenues to fight GBM.
Fichier principal
Vignette du fichier
noac239.pdf (912.82 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04237361 , version 1 (11-10-2023)

Identifiants

Citer

Hala Awada, François Paris, Claire Pecqueur. Exploiting radiation immunostimulatory effects to improve glioblastoma outcome. Neuro-Oncology, 2023, 25 (3), pp.433-446. ⟨10.1093/neuonc/noac239⟩. ⟨hal-04237361⟩
18 Consultations
13 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More